Chronic Pediatric Conditions - USMLE Step 2

SECTION 1

Historical Context & Motivation

The recognition of chronic pediatric conditions as a distinct clinical domain evolved gradually over the twentieth century. For much of human history, infectious diseases dominated pediatric morbidity and mortality, leaving chronic illnesses largely unrecognized or untreated. The advent of vaccines, antibiotics, and improved sanitation shifted the epidemiologic landscape, revealing a substantial burden of non-communicable and chronic diseases in children. This paradigm shift—often called the epidemiologic transition—compelled the medical community to develop structured approaches to conditions such as asthma, type 1 diabetes mellitus, cystic fibrosis, sickle cell disease, juvenile idiopathic arthritis, and epilepsy. Today, an estimated 15–20% of children in the United States live with at least one chronic condition, making this topic indispensable for any clinician preparing for the USMLE Step 2 examination.

1921 • Insulin Discovery

Banting and Best isolate insulin, transforming type 1 diabetes from a uniformly fatal disease into a manageable chronic condition in children.

1953 • Sickle Cell Molecular Basis

Linus Pauling and colleagues demonstrate that sickle cell disease arises from abnormal hemoglobin, inaugurating the era of molecular medicine and newborn screening programs.

1989 • CFTR Gene Identified

Discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene opens pathways for targeted therapies, fundamentally altering the prognosis of CF.

2007 • NAEPP EPR-3 Guidelines

The National Asthma Education and Prevention Program publishes the Expert Panel Report 3, establishing evidence-based stepwise therapy for pediatric asthma management.

2019 • CFTR Modulator Triple Therapy

FDA approves elexacaftor/tezacaftor/ivacaftor (Trikafta), a breakthrough CFTR modulator effective in approximately 90% of CF patients, dramatically improving survival projections.

These milestones illustrate a recurring theme: advances in genetics, immunology, and pharmacology have progressively converted formerly fatal pediatric diseases into chronic conditions requiring lifelong surveillance. The central clinical question that this lesson addresses is: How do you systematically diagnose, classify, and manage the major chronic pediatric conditions encountered on the USMLE Step 2?

SECTION 2

Core Principles & Definitions

A chronic pediatric condition is generally defined as a health condition lasting or expected to last at least 12 months and either requiring ongoing medical attention or limiting activities of daily living. These conditions share several unifying principles that guide clinical reasoning across different disease categories. Understanding these cross-cutting concepts allows you to construct a coherent framework rather than memorizing each disease in isolation.

Stepwise & Severity-Based Management

Most chronic pediatric diseases employ a severity classification system (e.g., intermittent vs. persistent asthma, HbSS vs. HbSC in sickle cell) that directly determines therapy intensity. Treatment is escalated or de-escalated based on symptom control at regular intervals.

Multidisciplinary Team Care

Optimal outcomes require coordination among pediatricians, subspecialists, nutritionists, social workers, and psychologists. The medical home model is central to chronic disease management in children.

Growth & Developmental Monitoring

Unlike adults, children are actively growing. Chronic conditions and their treatments can affect linear growth, pubertal development, and neurocognitive milestones, necessitating routine anthropometric and developmental surveillance.

Transition of Care

Adolescents with chronic conditions require a structured transition plan to adult-oriented healthcare to avoid lapses in follow-up, medication adherence, and disease surveillance during the vulnerable 18–25 age range.

Genetic & Environmental Interplay

Many chronic pediatric diseases involve a genetic predisposition modified by environmental triggers (e.g., atopic triad in asthma, viral triggers in type 1 diabetes). Understanding this interplay is essential for counseling and prevention.

✦

KEY TAKEAWAY

Think of managing a chronic pediatric condition like piloting a long-haul flight: you need a structured flight plan (stepwise management), a skilled crew (multidisciplinary team), constant monitoring of altitude and fuel (growth and disease control parameters), and a smooth handoff to the next air-traffic controller at your destination (transition of care). The disease itself is the weather—partly genetic turbulence you can't change, partly environmental conditions you can navigate.

SECTION 3

Visual Explanation — Overview of Major Chronic Conditions

This organ-system map displays six major categories of chronic pediatric conditions. Each box contains the key diagnostic markers and first-line treatments. The cross-cutting themes at the bottom apply universally to every chronic pediatric condition and represent high-yield USMLE concepts.

The diagram above organizes the most frequently tested chronic pediatric conditions by affected organ system. Note that many conditions span multiple systems—for instance, cystic fibrosis involves the respiratory, gastrointestinal, and endocrine systems simultaneously. The cross-cutting themes at the bottom represent the management scaffolding that applies to every condition: growth monitoring is essential because chronic inflammation, malabsorption, and glucocorticoid use can all impair linear growth. Immunization schedules must be adapted for immunocompromised children—live vaccines are generally contraindicated in patients on high-dose immunosuppression. On USMLE Step 2, clinical vignettes frequently integrate these cross-cutting principles into disease-specific scenarios, testing your ability to synthesize rather than simply recall isolated facts.

SECTION 4

Pathophysiologic Mechanisms & Key Diagnostics

Asthma

Pediatric asthma is a chronic inflammatory airway disease driven by Th2-mediated immune responses involving interleukins IL-4, IL-5, and IL-13. These cytokines promote eosinophilic infiltration, goblet cell hyperplasia with mucus hypersecretion, and smooth muscle hypertrophy, culminating in reversible airflow obstruction. Spirometry demonstrates a reduced FEV₁/FVC ratio that improves by ≥12% (and ≥200 mL in older children) after bronchodilator administration. Classification follows four severity tiers: intermittent, mild persistent, moderate persistent, and severe persistent. The stepwise therapy paradigm begins with a short-acting β₂-agonist (SABA) as needed for intermittent disease and escalates through low-dose, medium-dose, and high-dose inhaled corticosteroids (ICS) combined with long-acting β₂-agonists (LABA) or leukotriene receptor antagonists. For refractory cases, biologic agents such as omalizumab (anti-IgE) or mepolizumab (anti-IL-5) may be considered.

Type 1 Diabetes Mellitus

Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of pancreatic β-cells, typically mediated by CD8⁺ T lymphocytes. Autoantibodies—including anti-GAD65, anti-IA-2, anti-insulin, and anti-ZnT8—are detectable months to years before clinical onset. The classic presentation involves polyuria, polydipsia, polyphagia, and weight loss, and can progress to diabetic ketoacidosis (DKA) with Kussmaul respirations, abdominal pain, and altered mental status. Diagnosis is confirmed by a fasting glucose ≥126 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. Management centers on basal-bolus insulin therapy using long-acting insulin (glargine, detemir) for basal needs and rapid-acting insulin (lispro, aspart) for prandial coverage and correction. Continuous glucose monitors and insulin pumps increasingly augment this regimen. The target HbA1c for most pediatric patients is <7.0%, balanced against hypoglycemia risk.

Sickle Cell Disease

Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy caused by a point mutation in the HBB gene (Glu6Val), producing hemoglobin S (HbS). Under deoxygenated or dehydrated conditions, HbS polymerizes, distorting erythrocytes into rigid sickle shapes that occlude the microvasculature and trigger vaso-occlusive crises (VOC). Chronic hemolysis leads to anemia, cholelithiasis, and compensatory bone marrow expansion. Life-threatening complications include acute chest syndrome (new pulmonary infiltrate + respiratory symptoms), splenic sequestration (rapid splenic enlargement with hemoglobin drop ≥2 g/dL), and stroke (screened via transcranial Doppler). Disease-modifying therapy includes hydroxyurea (increases HbF production), chronic transfusion programs, and potentially curative hematopoietic stem cell transplantation. Penicillin prophylaxis is mandatory from diagnosis until at least age 5 to prevent overwhelming Streptococcus pneumoniae sepsis due to functional asplenia.

Cystic Fibrosis

Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CFTR gene encoding a chloride/bicarbonate channel. The most common mutation, F508del, leads to misfolded protein that is degraded before reaching the cell membrane. Defective chloride transport produces thick, dehydrated secretions across multiple organ systems: bronchiectasis and recurrent pulmonary infections (classically Pseudomonas aeruginosa), pancreatic insufficiency with fat-soluble vitamin malabsorption, meconium ileus in neonates, and infertility in males (congenital bilateral absence of the vas deferens). The diagnostic gold standard is a sweat chloride test ≥60 mmol/L. Management includes airway clearance techniques, inhaled dornase alfa, pancreatic enzyme replacement, and CFTR modulator therapy (e.g., elexacaftor/tezacaftor/ivacaftor for patients with at least one F508del allele).

SECTION 5

Classification & Diagnostic Workup

Upper panel: Asthma severity and corresponding stepwise therapy (Steps 1–6). Lower panel: Diagnostic and monitoring summary for five high-yield chronic pediatric conditions. TCD = transcranial Doppler; NBS = newborn screen; PFTs = pulmonary function tests; ILAR = International League of Associations for Rheumatology.

The upper portion of the diagram codifies the EPR-3 stepwise therapy guidelines for asthma, which is among the most commonly tested frameworks on USMLE Step 2. It is critical to recognize that treatment decisions should be guided not only by initial severity classification but also by ongoing assessment of control. A patient on Step 2 therapy who remains symptomatic should be stepped up to Step 3, whereas a patient who has been well-controlled for ≥3 months may be stepped down. The lower portion summarizes the initial diagnostic workup and longitudinal monitoring tools for five conditions. A key exam pearl: transcranial Doppler (TCD) ultrasound is performed annually in children with SCD beginning at age 2 to identify those at high risk for stroke, who are then started on chronic transfusion to maintain HbS <30%.

SECTION 6

Worked Example — Clinical Vignette

ℹ

CLINICAL VIGNETTE

A 4-year-old African American boy presents to the emergency department with acute onset of severe bilateral hand and foot swelling, fever of 38.5 °C, and irritability. His parents report he was diagnosed at birth with "sickle cell" via newborn screening and is taking penicillin prophylaxis daily. Hemoglobin is 7.2 g/dL (baseline 8.0 g/dL), WBC 14,000/μL, reticulocyte count 8%. Peripheral smear shows sickled cells and Howell-Jolly bodies. What is the diagnosis, and how should this patient be managed?

Step-by-Step Clinical Reasoning

1
Step 1 — Identify the Presentation Pattern

A young child with known sickle cell disease (SCD) presenting with dactylitis—painful swelling of the hands and feet—accompanied by fever and a mild drop from baseline hemoglobin. Dactylitis is the most common initial manifestation of SCD in children aged 6 months to 3 years but can occur up to age 5. The presence of Howell-Jolly bodies confirms functional asplenia.

Diagnosis: Vaso-occlusive crisis manifesting as dactylitis (hand-foot syndrome)
2
Step 2 — Assess for Complications

Fever in a child with SCD and functional asplenia is a medical emergency due to the risk of overwhelming pneumococcal sepsis. Even though dactylitis is the likely explanation for fever, you must rule out bacteremia. The hemoglobin drop of only 0.8 g/dL from baseline makes splenic sequestration less likely (which typically presents with a drop ≥2 g/dL and rapidly enlarging spleen). A chest X-ray should be obtained to rule out acute chest syndrome if respiratory symptoms develop.

Priority: Blood cultures × 2 and empiric IV ceftriaxone for febrile SCD patient
3
Step 3 — Initiate Acute Management

Acute VOC management includes aggressive IV hydration (1–1.5× maintenance), parenteral analgesics (IV morphine or ketorolac for pain), and empiric antibiotics pending culture results. NSAIDs can serve as adjunctive analgesia. Monitor oxygen saturation and provide supplemental O₂ if SpO₂ falls below 95%. Incentive spirometry is recommended in admitted patients to prevent atelectasis and acute chest syndrome.

IV fluids + IV analgesics + empiric ceftriaxone + SpO₂ monitoring
4
Step 4 — Plan Long-Term Disease Modification

After the acute crisis resolves, this patient's recurrent VOCs should prompt consideration of disease-modifying therapy. Hydroxyurea is the first-line disease-modifying agent for children with SCD, recommended starting at age 9 months regardless of clinical severity per the 2014 NHLBI guidelines. Hydroxyurea increases fetal hemoglobin (HbF) production, which inhibits HbS polymerization. Additionally, confirm the patient's vaccination status: pneumococcal conjugate (PCV13) and polysaccharide (PPSV23) vaccines, meningococcal vaccines, and annual influenza vaccination are essential. Schedule transcranial Doppler for stroke risk assessment.

Initiate hydroxyurea, verify immunizations, schedule annual TCD

SECTION 7

Comparative Features & Common Pitfalls

Feature	Asthma	Cystic Fibrosis	Sickle Cell Disease
Inheritance	Multifactorial / polygenic	Autosomal recessive	Autosomal recessive
Newborn Screen	Not applicable	Immunoreactive trypsinogen (IRT)	Hb electrophoresis
Confirmatory Dx	Spirometry with reversibility	Sweat chloride ≥60 mmol/L	Hb electrophoresis (HbSS, HbSC)
Key Acute Emergency	Status asthmaticus	Pulmonary exacerbation / massive hemoptysis	Acute chest syndrome / splenic sequestration
Controller Therapy	ICS ± LABA ± LTRA	CFTR modulators + airway clearance	Hydroxyurea ± chronic transfusion
Infection Risk	Viral triggers (RSV, rhinovirus)	Pseudomonas aeruginosa colonization	Encapsulated organisms (S. pneumoniae)
Curative Option	None (may remit)	Lung transplant	Hematopoietic stem cell transplant

Comparison of Three High-Yield Chronic Pediatric Conditions

⚠

COMMON EXAM PITFALLS

Pitfall 1: Confusing asthma exacerbation with acute chest syndrome. Both feature wheezing and dyspnea, but acute chest syndrome requires a new pulmonary infiltrate on CXR in a patient with SCD. Pitfall 2: Forgetting penicillin prophylaxis in SCD. This is standard of care from diagnosis until at least age 5 and is frequently tested. Pitfall 3: Using a LABA as monotherapy in asthma. LABAs must always be combined with an ICS—monotherapy increases the risk of severe exacerbations and death. Pitfall 4: Misidentifying meconium ileus as Hirschsprung disease. Both cause neonatal bowel obstruction, but meconium ileus is pathognomonic for CF and presents with a microcolon on contrast enema, whereas Hirschsprung shows a transition zone on barium enema.

✦

KEY TAKEAWAY

When approaching a chronic pediatric condition on Step 2, use a systematic framework: identify the organ system, classify severity, confirm diagnosis with the gold-standard test, initiate disease-modifying therapy early, and anticipate the characteristic acute complications. This approach is analogous to an engineer's fault-tree analysis—you map out every potential failure mode (complication) for a system (disease) so you can install the right preventive safeguards (prophylaxis, screening) before a catastrophic failure (acute crisis) occurs.

SECTION 8

Connection to Advanced Therapies & Emerging Concepts

The management of chronic pediatric conditions is rapidly evolving, driven by advances in molecular biology, gene therapy, and precision medicine. Understanding the trajectory from established treatments to emerging therapies provides valuable context for both clinical practice and board examinations, as the USMLE increasingly incorporates questions about cutting-edge therapeutic modalities.

Condition	Current Standard of Care	Emerging / Advanced Therapy
Type 1 DM	Basal-bolus insulin, CGM, insulin pump	Teplizumab (anti-CD3 mAb) delays onset by ~2 yr in at-risk individuals; closed-loop artificial pancreas systems
Cystic Fibrosis	CFTR modulator triple therapy (elexacaftor/tezacaftor/ivacaftor)	mRNA-based CFTR restoration; gene editing (CRISPR-Cas9) trials for non-responsive mutations
Sickle Cell Disease	Hydroxyurea, chronic transfusion, HLA-matched HSCT	Gene therapy (lovotibeglogene autotemcel / exagamglogene autotemcel — CRISPR-based BCL11A disruption to reactivate HbF)
Asthma	Stepwise ICS ± LABA; biologics (omalizumab, mepolizumab)	Tezepelumab (anti-TSLP) for all asthma phenotypes regardless of eosinophil count; bronchial thermoplasty in adolescents
JIA	NSAIDs → MTX → biologics (etanercept, adalimumab, tocilizumab)	JAK inhibitors (tofacitinib) for refractory polyarticular JIA; treat-to-target strategies with imaging-guided remission goals

Current vs. Emerging Therapies for Chronic Pediatric Conditions

The approval of CRISPR-based gene therapy for sickle cell disease (exagamglogene autotemcel, Casgevy) in December 2023 marked a watershed moment in pediatric hematology. By disrupting the BCL11A enhancer in autologous CD34⁺ cells, the therapy reactivates fetal hemoglobin production, effectively converting the patient's hemoglobin phenotype from one dominated by HbS to one with substantial HbF. Early clinical data demonstrate near-complete resolution of vaso-occlusive crises in treated patients. Similarly, teplizumab (an anti-CD3 monoclonal antibody) became the first drug approved to delay the onset of stage 3 type 1 diabetes in high-risk individuals, signaling a shift from reactive management to disease interception. While these advanced therapies are unlikely to appear as isolated questions on Step 2, understanding their mechanisms reinforces the immunologic and genetic principles that underlie the conditions themselves.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A 10-year-old boy with a history of cystic fibrosis presents for a routine follow-up visit. His mother asks about the most common cause of mortality in patients with cystic fibrosis. Which of the following is the most accurate response?

A. Meconium ileus
B. Pancreatic insufficiency and malnutrition
C. Progressive pulmonary disease and respiratory failure
D. Hepatobiliary cirrhosis
E. Distal intestinal obstruction syndrome

Show answer

The correct answer is C. Progressive pulmonary disease and respiratory failure account for approximately 80% of mortality in cystic fibrosis patients. Chronic airway infection with organisms such as Pseudomonas aeruginosa leads to progressive bronchiectasis, declining lung function, and ultimately respiratory failure. Meconium ileus (A) is a neonatal presentation of cystic fibrosis that can be surgically managed and is not a leading cause of death. Pancreatic insufficiency and malnutrition (B) are significant sources of morbidity and are managed with pancreatic enzyme replacement therapy, but they are not the primary cause of mortality. Hepatobiliary cirrhosis (D) occurs in a subset of CF patients but accounts for a much smaller proportion of deaths compared to pulmonary disease. Distal intestinal obstruction syndrome (E) is a gastrointestinal complication that can be treated medically or surgically and is not a major cause of mortality.

Question 2: BASIC CALCULATION

A 7-year-old girl with persistent asthma has been using a low-dose inhaled corticosteroid daily but continues to have symptoms 4 days per week and nighttime awakenings 3 times per month. Her current FEV1 is 85% of predicted. Based on the NAEPP guidelines, how should her asthma be classified and what is the most appropriate next step in management?

A. Well-controlled asthma; continue current regimen
B. Not well-controlled asthma; step up to medium-dose inhaled corticosteroid
C. Very poorly controlled asthma; add oral corticosteroids
D. Not well-controlled asthma; add a short-acting beta-agonist for daily use
E. Well-controlled asthma; step down therapy to as-needed inhaled corticosteroid

Show answer

The correct answer is B. According to NAEPP guidelines, asthma is classified as 'not well-controlled' when symptoms occur more than 2 days per week or nighttime awakenings occur more than once per month, which applies to this patient with symptoms 4 days/week and 3 nighttime awakenings/month. The appropriate step-up therapy from low-dose inhaled corticosteroids is to increase to medium-dose inhaled corticosteroids (or alternatively add a long-acting beta-agonist or leukotriene receptor antagonist). Choice A is incorrect because her symptom frequency exceeds the thresholds for well-controlled asthma. Choice C is incorrect because 'very poorly controlled' asthma is defined by symptoms throughout the day and nighttime awakenings more than once per week; oral corticosteroids are reserved for acute exacerbations or severe persistent disease. Choice D is incorrect because short-acting beta-agonists are rescue medications and should not be prescribed for daily scheduled use. Choice E is incorrect because stepping down therapy is only appropriate when asthma has been well-controlled for at least 3 months, which is not the case here.

Question 3: INTERMEDIATE

A 14-year-old boy with sickle cell disease presents to the emergency department with sudden onset of fatigue, pallor, and tachycardia. His hemoglobin is 3.5 g/dL, down from his baseline of 8 g/dL. Reticulocyte count is 0.1%. Physical examination reveals mild splenomegaly. A peripheral blood smear shows no sickled cells and no spherocytes. Which of the following is the most likely diagnosis?

A. Splenic sequestration crisis
B. Aplastic crisis due to parvovirus B19 infection
C. Vaso-occlusive crisis
D. Autoimmune hemolytic anemia
E. Acute chest syndrome

Show answer

The correct answer is B. The key finding in this case is the severely depressed reticulocyte count (0.1%) in the setting of profound anemia, which is pathognomonic for an aplastic crisis. In sickle cell disease, aplastic crisis is most commonly caused by parvovirus B19, which infects erythroid progenitor cells and transiently halts red blood cell production. Splenic sequestration crisis (A) would present with a markedly enlarged spleen and an appropriately elevated reticulocyte count as the bone marrow attempts to compensate for red cells being trapped in the spleen; this patient has only mild splenomegaly and a very low reticulocyte count. Vaso-occlusive crisis (C) typically presents with severe pain rather than isolated anemia and would not cause a drop in reticulocyte count. Autoimmune hemolytic anemia (D) would show an elevated reticulocyte count as the marrow compensates for peripheral destruction, along with spherocytes on the peripheral smear. Acute chest syndrome (E) presents with fever, respiratory symptoms, and a new pulmonary infiltrate, none of which are described in this patient.

Question 4: APPLIED

A 5-year-old girl with a known history of type 1 diabetes mellitus is brought to the emergency department by her parents. She has had vomiting and abdominal pain for the past 12 hours. On examination, she is lethargic with Kussmaul respirations. Her blood glucose is 480 mg/dL, serum pH is 7.15, bicarbonate is 8 mEq/L, and serum potassium is 5.8 mEq/L. After initial fluid resuscitation with normal saline, an insulin drip is started. Two hours later, her serum potassium is 3.2 mEq/L. Which of the following best explains the rapid decline in serum potassium?

A. Excessive renal potassium losses from osmotic diuresis
B. Insulin-mediated intracellular shift of potassium
C. Dilutional effect from intravenous fluid administration
D. Correction of metabolic acidosis causing increased urinary potassium excretion
E. Gastrointestinal losses from persistent vomiting

Show answer

The correct answer is B. In diabetic ketoacidosis (DKA), patients typically have total body potassium depletion despite initially elevated serum potassium levels. The initial hyperkalemia is due to the transcellular shift of potassium out of cells caused by insulin deficiency, acidosis, and hyperosmolality. When insulin therapy is initiated, it activates the Na+/K+-ATPase pump, driving potassium back into cells, which causes a rapid and potentially dangerous decline in serum potassium. This is the most significant and rapid mechanism of potassium decline during DKA treatment. Osmotic diuresis (A) does contribute to total body potassium depletion prior to treatment but does not explain the acute rapid drop occurring specifically after insulin administration. Dilutional effect from IV fluids (C) can modestly lower potassium but would not account for a drop from 5.8 to 3.2 mEq/L in 2 hours. Correction of acidosis (D) does contribute to potassium shifting intracellularly, but the primary and most rapid mechanism is the direct effect of insulin on cellular potassium uptake. Gastrointestinal losses from vomiting (E) contribute to total body potassium depletion but do not explain the acute rapid decline temporally associated with insulin administration.

Question 5: CRITICAL THINKING

A 16-year-old boy with a history of Duchenne muscular dystrophy presents with progressive dyspnea over the past 6 months. He has been wheelchair-bound since age 12. He has a known scoliosis and uses bilevel positive airway pressure (BiPAP) at night. His most recent echocardiogram 1 year ago showed an ejection fraction of 45%. Current vital signs include heart rate 110/min, respiratory rate 24/min, blood pressure 100/60 mmHg, and oxygen saturation 92% on room air. Examination reveals jugular venous distension, an S3 gallop, bilateral crackles at the lung bases, and hepatomegaly. Which of the following is the most appropriate initial pharmacologic intervention for this patient's current presentation?

A. Initiation of an ACE inhibitor and a beta-blocker
B. Intravenous furosemide
C. High-dose corticosteroids to slow disease progression
D. Digoxin for rate control
E. Intravenous dobutamine infusion

Show answer

The correct answer is B. This patient is presenting with acute decompensated heart failure (ADHF) as evidenced by jugular venous distension, S3 gallop, pulmonary crackles, and hepatomegaly in the setting of known Duchenne muscular dystrophy-associated cardiomyopathy. The most appropriate initial pharmacologic intervention for volume-overloaded decompensated heart failure is intravenous diuresis with furosemide to relieve congestion and improve symptoms. ACE inhibitors and beta-blockers (A) are cornerstones of chronic heart failure management and should be part of his long-term regimen, but they are not the initial intervention in acute decompensation; beta-blockers in particular should not be initiated during acute decompensation as they can worsen hemodynamics. High-dose corticosteroids (C) are used earlier in the course of Duchenne muscular dystrophy to prolong ambulation and slow skeletal muscle decline, but they do not address acute heart failure and may worsen fluid retention. Digoxin (D) may have a role in chronic heart failure management for symptom improvement but is not first-line for acute decompensated heart failure and is primarily used for rate control in atrial fibrillation, which is not described here. Intravenous dobutamine (E) is reserved for cardiogenic shock with evidence of end-organ hypoperfusion; while this patient has tachycardia and borderline blood pressure, he does not have overt cardiogenic shock, and diuresis should be attempted first.

SUMMARY

Lesson Summary

Summary

Chronic pediatric conditions represent a significant and growing burden in pediatric medicine, requiring a systematic approach to diagnosis and management. Asthma is managed via stepwise therapy based on severity classification (intermittent through severe persistent), with inhaled corticosteroids as the cornerstone controller. Type 1 diabetes requires basal-bolus insulin with target HbA1c <7.0% and vigilance for DKA. Sickle cell disease management hinges on hydroxyurea, penicillin prophylaxis, annual TCD screening starting at age 2, and chronic transfusion for abnormal TCD velocities (≥200 cm/sec). Cystic fibrosis is confirmed by sweat chloride ≥60 mmol/L and managed with airway clearance, pancreatic enzyme replacement, and CFTR modulators.

Across all chronic pediatric conditions, the cross-cutting themes of growth monitoring, immunization optimization, psychosocial support, multidisciplinary team care, and transition planning to adult care are essential for optimal outcomes. Emerging therapies including CRISPR-based gene therapy for SCD and teplizumab for T1DM prevention are reshaping the therapeutic landscape, underscoring the importance of understanding the molecular pathophysiology that underlies each condition.